Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.

Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: cyclo(Trp-Asp-Pro-Val-Leu)

Criteria

Inclusion Criteria:

• STEMI patients (defined as: Evidence of ischemic chest pain for >30 minutes within <12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 >1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery.

Exclusion Criteria:

• Significant liver disease

• Thrombolytic therapy

• History of prior myocardial infarction

• Current atrial fibrillation

• History of congestive heart failure

• History of migraine headache

• Significant valvular heart disease, primary myocardial disease

• Cardiogenic shock (sRR <90mmHg or need for inotropic support)

• Child-bearing potential

• Inability to read, understand and sign the informed consent

• Life expectancy <3y

• Prior organ transplantation

• Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives

• Participation in another clinical study

• Metal implants contraindicating CMR